# Phase II Clinical Trial of the Safety and Efficacy if a NOX1/4 Inhibitor in IPF

> **NIH NIH P01** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2020 · $142,856

## Abstract

Idiopathic pulmonary fibrosis (IPF) is a morbid fibroproliferative lung disease of older adults that causes
progressive dyspnea and hypoxemia. Current treatments for IPF are only partly efficacious, and often have
unacceptable side-effects. Development of a safe, effective IPF therapy would be a major advance.
 Reactive oxygen species (ROS) generated by NADPH oxidases (NOX) play an important role in the
development of fibrosis. Investigations during Cycle 1 of this tPPG showed that inhibition of NOX4 with a
small molecule pharmaceutical (GKT137831) decreased the severity of the pulmonary abnormality and
improved survival in an animal model of persistent fibrosis. GKT137831 treatment also reduces ROS
production and decreases ECM production in other animal models of liver, kidney, and cardiac fibrosis.
Importantly, GKT137831 has a good safety profile in early phase human trials for other indications.
 Other studies conducted during Cycle I of this tPPG showed that o,o’-dytyrosine, which is a ROS-induced
covalent modification of protein-tyrosine residues, was increased 18-fold in the plasma of IPF patients
relative to healthy controls. ECM turnover is also a fundamental process in IPF pathogenesis, and increases
in the circulating products of collagen digestions by matrix metalloproteinases, including the neoepitope
C1M, were recently shown to predict lung disease progression in IPF patients.
 We hypothesize that treatment with the NOX1/4 inhibitor GKT137831 will reduce oxidative injury in IPF
patients, and propose here a pilot study to test this hypothesis.
 The goal of Specific Aim 1 is to conduct a double-blinded Phase IIB clinical trial in 60 ambulatory IPF
subjects at five major medical centers. Subjects will be randomized 1:1 to GKT137831 or placebo, and
treated for six months. The primary endpoint of this trial will be treatment effects on o,o'-dityrosine plasma
levels, measured pretreatment, and at six week intervals. We hypothesize GKT137831 therapy will reduce
plasma levels of o,o'-tyrosine, reflecting a drug-induced reduction of ROS injury.
 Specific Aim 2 will determine effects of GKT137831 compared to placebo, on a.) Collagen degradation
product C1M concentrations in sera; b.) Forced vital capacities; c.) Six-minute walk distances; and d.)
Adverse event (AE) rates. We hypothesize GKT137831 therapy will decrease C1M, and have an acceptable
AE profile. The clinical measures will facilitate detection of an unprecedented benefit of this novel approach.
 This highly innovative clinical trial could provide evidence that selective NOX inhibition is safe and
beneficial in IPF patients. Results of this study will help to confirm and establish methods, and provide the
rationale that will facilitate and justify subsequent definitive trials to evaluate the clinical benefits of NOX
inhibitors in IPF. This research has the potential to be paradigm-shifting, will fill several existing gaps, and
could ultimately extend the lives of many future patients...

## Key facts

- **NIH application ID:** 9980989
- **Project number:** 5P01HL114470-08
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** STEVEN R DUNCAN
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $142,856
- **Award type:** 5
- **Project period:** — → 2020-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9980989

## Citation

> US National Institutes of Health, RePORTER application 9980989, Phase II Clinical Trial of the Safety and Efficacy if a NOX1/4 Inhibitor in IPF (5P01HL114470-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9980989. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*